anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mast cells are effector cells known to contribute to allergic airway disease. When activated, mast cells release a broad spectrum of inflammatory mediators, including the mast cell-specific protease carboxypeptidase A3 (CPA3). The expression of CPA3 in the airway epithelium and lumen of asthma patients has been associated with a Th2-driven airway inflammation. However, the role of CPA3 in asthma is unclear and therefore, the aim of this study was to investigate the impact of CPA3 for the development and severity of allergic airway inflammation using knockout mice with a deletion in the Cpa3 gene. We used the ovalbumin (OVA)- and house-dust mite (HDM) induced murine asthma models, and monitored development of allergic airway inflammation. In the OVA model, mice were sensitized with OVA intraperitoneally at seven time points and challenged intranasally (i.n.) with OVA three times. HDM-treated mice were challenged i.n. twice weekly for three weeks. Both asthma protocols resulted in elevated airway hyperresponsiveness, increased number of eosinophils in bronchoalveolar lavage fluid, increased peribronchial mast cell degranulation, goblet cell hyperplasia, thickening of airway smooth muscle layer, increased expression of IL-33 and increased production of allergen-specific IgE in allergen-exposed mice as compared to mocktreated mice. However, increased number of peribronchial mast cells was only seen in the HDM asthma model. The asthma-like responses in Cpa3-/- mice were similar as in wild type mice, regardless of the asthma protocol used. Our results demonstrated that the absence of a functional Cpa3 gene had no effect on several symptoms of asthma in two different mouse models. This suggest that CPA3 is dispensable for development of allergic airway inflammation in acute models of asthma in mice.
The present invention provides compositions and methods for making and using antibodies. A pharmaceutical composition of the invention comprises a selected antigen and a Candida spp. antigen. Selected antigens include, for example, antigens derived from bacteria, yeasts, rickettsias, protozoas, viruses, parasites, and components or fragments thereof. Preferred compositions disclosed include antigens selected from Cryptosporidium spp. and Clostridium spp. The invention further provides for immunizing an animal with a composition of the invention to prepare a composition of immunoglobulins reactive with the selected antigen. The composition of immunoglobulins can be included in nutraceuticals that are ingested or administered enterally.
The first cohort =1X10 7 cf expanded cells/kg. The second cohort = 5x10 7 expanded cells/kg. The second cohort = 1X10 8 expanded cells/kg.
The present invention relates to a kind of Anthraquinone dimer derivative and preparation method thereof and application, during preparation first in bacterium culture medium to deriving from South China Sea soft coral Sarcophyton? sp. endogenetic fungus Alternaria? sp. (ZJ-2008003) carries out spawn culture, fermentation culture in the fermentation medium again, by gained filtering fermentation liquor, removing filtrate, obtain thalline, by gained thalline methanol extraction; Silica gel column chromatography, Sephadex is carried out after extracting solution is concentrated? prepared by LH-20 gel filtration chromatography, high performance liquid chromatography, concentrated by gained elutriant, obtain red powder, Anthraquinone dimer derivative alterporriol? Q and alterporriol? R.The Anthraquinone dimer derivative that the present invention derives from thalassiomycetes has strong antivirus action, effectively can suppress porcine reproductive and respiratory syndrome virus (PRRSV), can be used as antiviral, and raw material can carry out scale operation, has a extensive future.
Attenuated E. necatrix suitable for use in the production of a live vaccine is produced by passaging pathogenic E. necatrix in embryonated eggs for a sufficient number of passages i.e. from about 20 up to about 50 or more egg passages. The live egg-attenuated E. necatrix of the invention may be formulated in vaccines, e.g. feed or drinking water vaccines, for prevention and control of coccidiosis in poultry, usually with other strains of Eimeria (i.e. E. acervulina, E. brunetti, E. maxima, E. mivaii, E. praecose and E. tenella) as live pathogenic strains thereof or preferably attenuated non-pathogenic lines thereof. In a perferred embodiment the egg-attenuated E. necatrix of the invention is formulated in a vaccine comprising attenuated, precocious E. acervulina.
A new circulating form of soluble human tissue factor was identified. This new form of human tissue factor appears to be the result of alternative splicing and is therefore referred to as “alt-hTF.” Alt-hTF mRNA was detected in a cell line, HL-60. The cDNA region encoding the entire open reading frame of alt-hTF was cloned. The sequence encoding the alt-hTF mature peptide was expressed in bacteria. alt-hTF consists of the first 166 amino acids of membrane bound TF, and a 40 amino acid C-terminal region unique to alt-hTF. Alt-hTF is likely to be a useful target for compounds to inhibit clotting and to treat disorders associated with elevated TF. It may also be useful as a target for antibodies selectively reactive with alt-hTF, to remove it from the circulation for treatment of clotting or other disorders associated with elevated or abnormal levels of TF, including thrombotic conditions, cardiovascular disorders, DVT, DIC, and possibly metastatic cancers.
Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
Patients receive elimusertib PO QD on days 2, 3, 9, 10, 16, and 17 of cycle 1 and 2, and on days 2, 3, 9, and 10 of each cycle thereafter. Patients receive irinotecan IV over 90 minutes on days 1, 8, and 15 of cycle 1 and 2, and on days 1 and 8 of each cycle thereafter. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
Algorithm Guided Treatment (AGT) strategies include two steps. In the first step, participants will be randomly assigned to escitalopram (10-20mg/d) or mirtazapine (30-45mg/d) group. In the second step those non-remitted will be allocated into a set of different intervention groups including mirtazapine monotherapy (only for those taken escitalopram in the first step), escitalopram monotherapy (only for those taken mirtazapine in the first step), or combination therapies (i.e. escitalopram plus mirtazapine, escitalopram or mirtazapine plus either modified electroconvulsive therapy with 6-10 sessions or repetitive transcranial magnetic stimulation with 20 sessions respectively) according to intent-to-treat principle. Medication dosage in combination therapy has the same range as the first.
Participants will be managing their PKU with diet alone. Participants in the diet-only control arm will be required to maintain and adjust dietary and medical protein food intake through Week 72, initiating pegvaliase treatment beginning Week 73 and, from Weeks 73 through 215.
ON-01: 1ml intratumoral injection of ON-01. ONF: 100 mg/kg/day orally after operation for 20 consecutive days.
In addition to standard FM treatment at the Pain Clinic, patients who are randomized to the treatment will meet with a sleep physician for possible therapy with a Continuous Positive Airway Pressure (CPAP) machine. A CPAP titration study will be arranged for in a laboratory setting, where in addition to the regular parameters of a diagnostic sleep study, CPAP will be titrated upwards starting from 5cm H2O to an optimal setting where the obstructive respiratory events are abolished. Patients will undergo regular follow-up as determined by their sleep physician. Adherence to CPAP treatment will be recorded at follow-up visits.
Friendship network members will also consist of sexually experienced females, aged 13 years and older. Although most members are expected to be of African American race and/or Hispanic/Latina ethnicity, all races and ethnicities will be included.
Objective: This is the first clinical trial to evaluate the analgesic effect of 10 and 20 mg of morphine used in a postoperative dressing with patients after surgical debridement of burn wounds. Approach: In this randomized controlled trial, 20 adult patients with third-degree flame burns, who had undergone surgical debridement under general anesthesia, were randomly assigned to either group A, whose members were treated with a burn dressing that contained 10 mg of morphine, or group B, whose members were treated with a burn dressing that contained 20 mg of morphine; the dressing was also soaked with octenidine and phenoxyethanol in the case of both groups. The plasma morphine concentrations were measured 1, 2, 3, and 6 h after surgery, while the level of pain intensity was determined on the Numeric Pain Rating Scale (NRS), and the occurrence of side effects was observed. Results: The serum morphine concentration levels were very low, but statistically different between the two groups at all time points. The NRS value was similar in both groups at all time points (p > 0.05). Despite this, in group B, the NRS value was 0 in all patients in postoperative hours 1, 2, and 3. No adverse effect of morphine sulfate was observed in any patient. Innovation: This project is the first clinical study to have demonstrated that morphine administered in dressings in concentrations of 0.02-0.08 mg/mL significantly reduces the occurrence of pain. Conclusion: The use of morphine in dressings after surgical treatment of burn wounds is very effective when it comes to pain management and is safe for the patient.
In this Phase 2, open-label, dose-rising study, subjects with high grade (CIN 2 or 3) CIN will receive once-weekly topical application of SOR007 ointment to the ectocervix for four weeks. Subjects will be enrolled in three dose-escalating cohorts of three subjects assigned consecutively to receive 0.15%, 1.0%, or 2.0% SOR007 ointment. At the final study visit (Visit 7) subjects will undergo an excision or punch biopsy to record the stage of CIN. PK samples will be obtained post-application on Day 0 at 1, 2, 4, 6, and 24 hours' post-application on Day 1. Additional PK samples will be collected at each visit. Plasma samples for PK analysis on Days 7, 14 and 21 will be collected prior to SOR007 application.

The Medical Monitor will review all available data prior to dose escalation. Dose-escalation of SOR007 will be determined by the Medical Monitor. This will be repeated for each escalated dose until all dose levels have been enrolled or a dose is determined unsafe. Safety will be assessed in an ongoing manner and formal safety reviews will be conducted twice for each cohort: after Day 14 and after Day 49 of the last subject in the cohort. If a safety or tolerability issue becomes apparent in a cohort, an additional three subjects will be enrolled at that dose level, for a maximum of six subjects in that cohort. If ≥ 1 safety or tolerability issue occurs in the additional 3 subjects, the prior dose-level will be determined to be the highest dose with an acceptable safety and tolerability profile. If no further safety and tolerability issues are identified in the expanded cohort, dose-escalation will continue.

Once the highest dose with an acceptable safety and tolerability profile has been determined by the Medical Monitor, PI, and Sponsor Medical Director, a further 3 subjects will be enrolled to that dose level in order to increase the subject numbers.
PROBLEM TO BE SOLVED: To provide an image processor enabling an operator to perform more detailed diagnosis by enabling designation of an enlarged area to be carried out three-dimensionally for three-dimensional reconstruction data, and enlarging all of axial, coronal and sagital images through enlarging re-computation. SOLUTION: The axial image 2, the coronal image 4 and the sagital image 6 are outputted for display on a display device 10 as shown in Figure 3. A tomogram which the operator wants to diagnose is selected for each of the triaxial tomograms 2, 4 and 6. For one of the three tomograms 2, 4 and 6 displayed (axial image 2 in Figure), an enlarged area is dragged and inputted by use of a mouse so that it contains a lesion part which the operator wants to enlarge. For the other two of the tomograms (coronal image 4 and sagital image 6), an area is designated automatically and enlarging re-computation process is effected on the basis of the enlarged area designated. The axial image, the coronal image and the sagital image enlarged are displayed on the display device 10.
Traditional oblique calcaneus osteotomy through a lateral approach. After a 10mm displacement, the osteotomy will be fixed with two 4.0mm bio-integrative cannulated screws.
The etiology of idiopathic pain conditions, such as Provoked vulvodynia (PV), is multifactorial. The efficiency of venlafaxine, serotonin-noradrenaline reuptake inhibitor (SNRIs) in modulating vulvar pain led to the hypothesis that PV might involve central mechanisms. Here, we investigate whether vulvar pain is associated with gene-expression changes in mood, stress and pain systems, including amygdala (Amg), medial prefrontal cortex (mPFC), and periaqueductal gray matter (PAG). Additionally, we examined the analgesic and anxiolytic effects of venlafaxine. We found that the development of chronic vulvar pain in an animal model of PV is associated by overexpression of genes related to neuronal-activity and neuroinflammation in the Amg, mPFC, and PAG. Additionally, changes in the expression of GABA and serotonin synthesis, and reuptake were noted in the Amg and mPFC. Unsurprisingly, anxiety-like behavior and emotional-disorder were observed in rats with chronic vulvar pain. Nevertheless, treatment with venlafaxine (37.5 mg/kg) for one month significantly improves the vulvar hypersensitivity, as well as reduces the anxiety level. More critically, the long-term gene expression adaptation in serotonin receptor and synthesis, GABA synthesis, neuroplasticity, and neuroinflammation in the Amg, mPFC, and PAG, were modulated by venlafaxine in rats with vulvar pain. Our findings suggest that vulvar hypersensitivity induced by inflammation might associated with gene expression changes in brain areas that are involved in mood, stress and pain regulation. These changes probably play a role in central sensitization, and anxiety. Strikingly, enhancing the activity of serotonin and noradrenaline via venlafaxine treatment in rats with vulvar pain induces analgesic and anxiolytic effects.
Topical compsn. for treatment of acne is a lotion or cream contg. 1-10wt.% of O-acetylsalicyloyl peroxide of formula (I) (where R1 and R2 are H; and R is Me). Cpd. (I) has the desirable antiacne effects of a mixt. of benzoyl peroxide and salicylic acid (as described in DT 2418386), and it also has potent antibacterial activity.
PURPOSE: To obtain a composition for treating ophthalmic diseases containing an agent in microcapsules consisting of a biodegradable polymer, liposome, etc., capable of being introduced into an eye chamber and able to release at such a speed that it gives effective dose of the agent for a long period. CONSTITUTION: This is a transplanting material containing an ophthalmic disease-treating agent in microcapsules, capable of slowly releasing the agent for a long period when it is introduced into an eye chamber, able to treat the state, disease and disorder of an eye and having an average particle diameter of 10-250μm. The microcapsules are composed of a biodegradable polymer or liposome. As the biodegradable polymer, a polymer of a hydroxyl aliphatic carboxylic acid (e.g. a polymer of D-lactic acid, L-lactic acid, glycolic acid, etc.) or a polysaccharide (e.g. calcium alginate or carboxymethyl cellulose ester) is preferable. The liposome preferably has 10-50 mol% steroid, and the balance is an aliphatic acid, an organic acid ester and an inorganic acid ester.
PURPOSE: To accelerate the treatment of laceration, incisure or a damage after incision, or the ordinary non-vascular semilunar tissues after rupture by applying an effective dose of angiogenesis factors near the damaged tissues. CONSTITUTION: The angiogenesis factors are transplanted near the damaged section or immediately adjacent thereto or is more preferably applied or transplant in direct contact with the damaged tissues in, for example, the form of a compsn. contg. the angiogenesis factors and pharmaceutically permissible nontoxic carriers. These carriers may be liquid or solid and may be, for example, polymers, methyl cellulose or copolymers of ethylene and vinyl acetate or other polymer compsn. which slowly releases the angiogenesis factors over a long time. In the case of the latter, the angiogenesis factors are in the form of time limit release implants.
The disclosure is related to a system and method for patient-staff acknowledgment. The system and method includes activating a receiver of a wireless staff member device to receive a first signal within a threshold distance from a wireless patient device. The receiver being activated for a predetermined activation time, by affecting a switch of the wireless staff member device. Activating a transmitter of the wireless patient member device to transmit the first signal by affecting a switch of the wireless patient device. Transmitting a second signal from a transmitter of the wireless staff member device when the receiver of the wireless staff member device is receiving the first signal within the predetermined activation time. Cancelling an alarm activated by the wireless patient member device when the receiver of the wireless patient device is receiving the second signal from the wireless staff member device.
Macrophage infiltration and accumulation in the atherosclerotic lesion are associated with plaque progression and instability. Depletion of macrophages from the lesion might provide valuable insights into plaque stabilization processes. Therefore, we assessed the effects of systemic and local macrophage depletion on atherogenesis. To deplete monocytes/macrophages we used atherosclerosis-susceptible Apoe- /- mice, bearing a MaFIA (macrophage-Fas-induced-apoptosis) suicide construct under control of the Csf1r (CD115) promotor, where selective apoptosis of Csf1r-expressing cells was induced in a controlled manner, by administration of a drug, AP20187. Systemic induction of apoptosis resulted in a decrease in lesion macrophages and smooth-muscle cells. Plaque size and necrotic core size remained unaffected. Two weeks after the systemic depletion of macrophages, we observed a replenishment of the myeloid compartment. Myelopoiesis was modulated resulting in an expansion of CSF1Rlo myeloid cells in the circulation and a shift from Ly6chi monocytes toward Ly6cint and Ly6clo populations in the spleen. Local apoptosis induction led to a decrease in plaque burden and macrophage content with marginal effects on the circulating myeloid cells. Local, but not systemic depletion of Csf1r+ myeloid cells resulted in decreased plaque burden. Systemic depletion led to CSF1Rlo-monocyte expansion in blood, possibly explaining the lack of effects on plaque development.
The invention belongs to the technical field of medicine preparation, and particularly relates to a new application of nobiletin and a composition thereof. It is applied to preparing the medicine for reducing the expression of P-gp in the synovial tissue of arthritis. The combination of nobiletin and methotrexate reduces cartilage and bone damage and ameliorates swelling and arthritic damage. On the other hand, nobiletin can reverse P-gp expression in the arthritic injured person, thereby reducing efflux and maintaining efficacy against methotrexate. The nobiletin and the methotrexate have obvious synergistic effect, and under the non-cytotoxic concentration of the nobiletin, the combined treatment of the nobiletin and the methotrexate can restore the growth inhibition and the apoptosis of RA-FLS/methotrexate cells. Nobiletin can be used as a potential chemosensitizer to overcome drug resistance in RA.
Primary root canals(n=20) were instrumented using rotary P1 Kedo-S Square files (Reeganz Dental Care Pvt. Ltd. India) at 300 rpm and 2.2N cm torque. The rotary files were used with an Endo-Mate DT endodontic motor (NSK, Tokyo, Japan) and EDTA gel 17% (Meta Biomed Co. Ltd, Chungbuk, Korea) was used before instrumentation.
Vitamin C (ascorbic acid, ascorbate) is an essential water soluble vitamin. Our studies at NIH were the first to demonstrate in healthy men and women how changes in a vitamin concentration in human plasma vary as a direct function of the amount ingested, over a wide range. ln the present study, we plan to achieve a prescorbutic vitamin C plasma concentration of approximately 5-10 micromolar in healthy human volunteers. We will gradually replete these subjects with incremental doses of vitamin C to measure how their plasma, red blood cell, and leukocyte concentrations will change as a function of the dose. We will also determine whether changes in vitamin C concentration result in changes in gene expression and metabolic profiles (metabolomics, lipidomics, proteomics).

Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection. At steady state of each of 4 to 5 doses, an apheresis procedure will be performed for collection of platelets and leukocytes. lt is anticipated subjects will be discharged in healthy condition after 20-26 weeks.
The specific carbohydrate diet has been shown to have beneficial effects on IBD and has been implemented in Seattle Children's IBD centre, with some patients using SCD either as primary or complementary therapy. The SCD is a nutritionally balanced diet focused on removing many complex carbohydrates such as grains, dairy products except for yoghurt fermented over 24 hours, vegetables rich in starch and sugars except for monosaccharides like in honey. Participants can eat meat but since it has to be unprocessed food the investigator's experience is that the amounts of meat are not very big. Fish, eggs, sea-food is allowed. Bread is baked from nut and almond flour.